Celltrion today presented the results of a two-year post-hoc analysis on subcutaneous infliximab (CT-P13 SC) dose escalation therapy at the UEG Week 2024 in Vienna. The findings indicate that dose escalation is an effective management strategy for patients experiencing loss of response in inflammatory bowel disease.
Company Information
Company
Celltrion
Location
Incheon, Seoul, South Korea
About
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for several products, enhancing its portfolio in the biopharmaceutical industry.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Celltrion ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
IncheonManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharma